JP2013082644A - Oral liquid medicine composition - Google Patents
Oral liquid medicine composition Download PDFInfo
- Publication number
- JP2013082644A JP2013082644A JP2011222409A JP2011222409A JP2013082644A JP 2013082644 A JP2013082644 A JP 2013082644A JP 2011222409 A JP2011222409 A JP 2011222409A JP 2011222409 A JP2011222409 A JP 2011222409A JP 2013082644 A JP2013082644 A JP 2013082644A
- Authority
- JP
- Japan
- Prior art keywords
- internal
- component
- taste
- kojin
- internal liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title abstract description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 36
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims abstract description 20
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims abstract description 12
- 239000004376 Sucralose Substances 0.000 claims abstract description 12
- 235000010358 acesulfame potassium Nutrition 0.000 claims abstract description 12
- 229960004998 acesulfame potassium Drugs 0.000 claims abstract description 12
- 239000000619 acesulfame-K Substances 0.000 claims abstract description 12
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims abstract description 12
- 235000019408 sucralose Nutrition 0.000 claims abstract description 12
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims abstract description 12
- 239000004386 Erythritol Substances 0.000 claims abstract description 11
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000019414 erythritol Nutrition 0.000 claims abstract description 11
- 229940009714 erythritol Drugs 0.000 claims abstract description 11
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000003205 fragrance Substances 0.000 claims description 10
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 235000019634 flavors Nutrition 0.000 claims description 7
- 239000000306 component Substances 0.000 claims 1
- 235000019640 taste Nutrition 0.000 abstract description 22
- 235000003599 food sweetener Nutrition 0.000 abstract description 7
- 239000003765 sweetening agent Substances 0.000 abstract description 7
- 239000004615 ingredient Substances 0.000 abstract description 4
- 235000002789 Panax ginseng Nutrition 0.000 abstract 2
- 239000002304 perfume Substances 0.000 abstract 1
- 230000000873 masking effect Effects 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- -1 fatty acid esters Chemical class 0.000 description 6
- 239000000284 extract Substances 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 229940101267 panthenol Drugs 0.000 description 2
- 235000020957 pantothenol Nutrition 0.000 description 2
- 239000011619 pantothenol Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 244000141353 Prunus domestica Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、生薬であるコウジンを含有する内用液剤組成物に関する。 The present invention relates to an internal-use liquid preparation composition containing kojin which is a crude drug.
コウジンは、強壮、強精作用を有する薬用ニンジンの一種の生薬である。コウジンは、神経を活発にして、胃腸などの体の機能を高めるため、食欲不振や胃もたれ、病中病後の体の弱っているときに内用薬として用いられる。 Koujin is a kind of medicinal carrot that has tonic and strong action. Koujin is used as an internal medicine when the body is weak after anorexia, stomach sag, or illness because it activates the nerves and enhances functions of the body such as the gastrointestinal tract.
しかし、コウジンは、苦味及び特有の異味を有し、特に内用液剤にしたときの異味は強い。従って、コウジンを含有する内用液剤の服用性は極めて悪い。 However, Koujin has a bitter taste and a peculiar taste and has a strong taste especially when it is used as a liquid for internal use. Therefore, the ingestibility of the internal solution containing kojin is very poor.
一方、生薬等の苦味のマスキングには、有機酸とフルーツ系香料の使用（特許文献１、２）や、脂肪酸エステル、果糖及び白糖の使用（特許文献３）等が行なわれている。 On the other hand, masking of bitter tastes such as herbal medicines uses organic acids and fruit flavors (Patent Documents 1 and 2), and uses fatty acid esters, fructose and sucrose (Patent Document 3).
しかしながら、前記特許文献１〜３の手段をコウジンを含有する内用液剤に適用した場合には、単なる苦味ではないコウジン特有の異味は十分にマスキングできず、甘味を強くすると全体の味が悪化してしまうという問題があることが判明した。
従って、本発明の課題は、コウジン特有の異味を十分にマスキングし、味が良好で服用感の良好な内用液剤を提供することにある。
However, when the means of Patent Documents 1 to 3 are applied to an internal solution containing koji, the unique taste of koji, which is not just bitter, cannot be sufficiently masked, and if the sweetness is increased, the overall taste deteriorates. It turned out that there was a problem that.
Accordingly, an object of the present invention is to provide an internal liquid agent that sufficiently masks the special taste unique to kojin and has a good taste and a good feeling.
そこで本発明者は、コウジンを含有する液剤に種々の成分を配合して、コウジン特有の異味のマスキングについて種々検討した結果、コウジンに、一定量のベンズアルデヒド含有香料と、クエン酸又はその塩と、エリストリール、スクラロース及びアセスルファムカリウムから選ばれる１種又は２種以上の甘味料とを組み合わせて配合すれば、コウジン特有の異味がマスキングでき、かつ服用感の良好な内用液剤が得られることを見出し、本発明を完成した。 Therefore, the present inventor formulated various ingredients in the liquid preparation containing kojin, and variously studied the masking of the peculiar taste of kojin, and as a result, a certain amount of benzaldehyde-containing fragrance, citric acid or a salt thereof, When combined with one or more sweeteners selected from Eristol, sucralose, and acesulfame potassium, it is possible to mask the special taste of Koujin and to obtain an internal solution with a good feeling of taking. The headline and the present invention were completed.
すなわち、本発明は、（Ａ）コウジン、（Ｂ）ベンズアルデヒド含有香料、（Ｃ）クエン酸又はその塩、並びに（Ｄ）エリスリトール、スクラロース及びアセスルファムカリウムから選ばれる１種又は２種以上の甘味料を含有し、成分（Ａ）と成分（Ｂ）の含有質量比（Ａ／Ｂ）が３０〜２００である内用液剤組成物を提供するものである。 That is, the present invention comprises (A) Kojin, (B) benzaldehyde-containing fragrance, (C) citric acid or a salt thereof, and (D) one or more sweeteners selected from erythritol, sucralose and acesulfame potassium. It contains and provides the liquid composition for internal use whose containing mass ratio (A / B) of a component (A) and a component (B) is 30-200.
本発明の内用液剤組成物は、有効量のコウジンを含有しており、コウジン特有の異味がマスキングされ、かつ全体の味のバランスが良好で服用感に優れる。 The liquid preparation composition for internal use of the present invention contains an effective amount of Koujin, masks the peculiar taste unique to Koujin, has a good overall taste balance, and is excellent in the feeling of dosing.
本発明の内用液剤組成物に用いられる（Ａ）コウジンは、薬用ニンジンの一種の生薬である。（Ａ）コウジンとしては、コウジンの乾燥粉末及びその抽出物のいずれも用いられる。コウジンの抽出物としては、コウジンの水、アルコール、含水アルコール等による抽出物が挙げられる。ここでアルコールとしてはエタノールが好ましい。
本発明の内用液剤組成物１００ｍＬ中のコウジンの含有量は、有効性、異味のマスキング効果の点から、乾燥固形分換算で１，０００〜１０，０００ｍｇが好ましく、１，２００〜８，０００ｍｇがより好ましく、１，２００〜６，０００ｍｇがさらに好ましく、２，０００〜６，０００ｍｇがさらに好ましい。
(A) Kojin used in the internal liquid composition of the present invention is a kind of herbal medicine of medicinal carrot. (A) As Koujin, both dried powder of Koujin and its extract are used. Examples of the extract of kojin include extracts of kojin from water, alcohol, hydrous alcohol and the like. Here, ethanol is preferable as the alcohol.
The content of kojin in 100 mL of the liquid preparation for internal use of the present invention is preferably 1,000 to 10,000 mg in terms of dry solid content, and 1,200 to 8,000 mg in terms of effectiveness and masking effect of taste. Is more preferable, 1,200 to 6,000 mg is more preferable, and 2,000 to 6,000 mg is more preferable.
本発明の内用液剤組成物に用いられる（Ｂ）ベンズアルデヒド含有香料としては、ベンズアルデヒド特有の香気を有する香料であればよく、バラ目バラ科サクラ属又はカリン属のフレーバーが好ましく、ウメ、アンズ、プルーン、サクランボ、カリン等の香りを有する天然香料又は調合香料がより好ましく、ウメ特有の香りを有するベンズアルデヒドを含有するウメフレーバーが、コウジンの異味のマスキング効果、服用感の点からさらに好ましい。
本発明においては、成分（Ａ）と成分（Ｂ）の含有質量比（Ａ／Ｂ）が３０〜２００であるのが、コウジンの異味のマスキングとさわやかな服用感を得る点で重要である。当該含有質量比（Ａ／Ｂ）は、３０〜１５０がより好ましく、４０〜１２０がさらに好ましい。
The (B) benzaldehyde-containing fragrance used in the internal liquid composition of the present invention may be a fragrance having a fragrance specific to benzaldehyde, and preferably has a flavor of the genus Rosaceae or the genus Karin. Natural fragrances or blended fragrances having a scent such as prunes, cherries, and karin are more preferable, and ume flavors containing benzaldehyde having a scent peculiar to ume are more preferable from the viewpoint of masking effect of kojin and taste.
In the present invention, the content mass ratio (A / B) of the component (A) and the component (B) is 30 to 200, which is important in terms of obtaining an unpleasant masking of Koujin and a refreshing feeling. The content mass ratio (A / B) is more preferably 30 to 150, and still more preferably 40 to 120.
本発明に用いられる（Ｃ）クエン酸又はその塩としては、クエン酸、クエン酸ナトリウム、クエン酸カリウム等のクエン酸のアルカリ金属塩等が挙げられ、クエン酸ナトリウムが好ましい。クエン酸とクエン酸アルカリ金属塩とを併用するのがより好ましく、クエン酸とクエン酸ナトリウムを併用するのがさらに好ましい。
本発明の内用液剤組成物１００ｍＬ中の成分（Ｃ）の含有量は、コウジンの異味のマスキング効果、服用感の改善の点から３００〜１０００ｍｇが好ましく、３５０〜９００ｍｇがより好ましく、４００〜８００ｍｇがさらに好ましい。
Examples of (C) citric acid or a salt thereof used in the present invention include alkali metal salts of citric acid such as citric acid, sodium citrate and potassium citrate, and sodium citrate is preferred. It is more preferable to use citric acid and alkali metal citrate in combination, and it is more preferable to use citric acid and sodium citrate in combination.
The content of the component (C) in 100 mL of the liquid preparation composition for internal use of the present invention is preferably 300 to 1000 mg, more preferably 350 to 900 mg, and more preferably 400 to 800 mg from the viewpoint of the masking effect of kojin's nasty taste and the feeling of taking. Is more preferable.
本発明に用いられる（Ｄ）エリスリトール、スクラロース及びアセスルファムカリウムから選ばれる１種又は２種以上の甘味料は、低カロリーで高い甘味度を有し、かつコウジン特有の異味のマスキング効果を有する。これらの甘味料は、１種又は２種以上を組み合わせて用いるのが好ましく、２種以上組み合わせるのがより好ましく、エリスリトール、スクラロース及びアセスルファムカリウムの３成分を組み合わせて用いるのがさらに好ましい。
本発明の内用液剤組成物１００ｍＬ中のエリスリトールの含有量は、コウジンの異味のマスキング効果及び服用感の点から、１，０００〜１０，０００ｍｇが好ましく、２，０００〜８，０００ｍｇがより好ましく、３，０００〜６，０００ｍｇがさらに好ましい。また、内用液剤組成物１００ｍＬ中のスクラロースの含有量は、コウジンの異味のマスキング効果の点から、４〜１００ｍｇが好ましく、４〜９０ｍｇがより好ましく、４〜５０ｍｇがさらに好ましい。また、内用液剤組成物１００ｍＬ中のアセスルファムカリウムの含有量は、コウジンの異味のマスキング効果の点から、４〜１００ｍｇが好ましく、４〜９０ｍｇがより好ましく、４〜５０ｍｇがさらに好ましい。
One or more sweeteners selected from (D) erythritol, sucralose, and acesulfame potassium used in the present invention have a low calorie, high sweetness, and a masking effect unique to kojin. These sweeteners are preferably used alone or in combination of two or more, more preferably in combination of two or more, and even more preferably in combination of three components of erythritol, sucralose and acesulfame potassium.
The content of erythritol in 100 mL of the liquid preparation composition for internal use of the present invention is preferably from 1,000 to 10,000 mg, more preferably from 2,000 to 8,000 mg, from the viewpoint of the masking effect of kojin and the taste of taking. 3,000 to 6,000 mg is more preferable. In addition, the content of sucralose in 100 mL of the internal liquid composition is preferably 4 to 100 mg, more preferably 4 to 90 mg, and still more preferably 4 to 50 mg, from the viewpoint of the masking effect of kojin. In addition, the content of acesulfame potassium in 100 mL of the internal liquid composition is preferably 4 to 100 mg, more preferably 4 to 90 mg, and even more preferably 4 to 50 mg from the viewpoint of the masking effect of kojin.
本発明の内用液剤組成物には、さらにコウジンの異味のマスキング効果に悪影響を及ぼさない限り、ベンズアルデヒド以外の成分を含有するフレーバー、他の薬効成分、エタノール、ｐＨ調整剤、保存剤、着色剤、可溶化剤、グリセリン、水等を配合することができる。ここで他の薬効成分としては、ビタミンＢ１、ビタミンＢ２、ビタミンＢ６、ビタミンＢ１２、ビタミンＥ、ビタミンＥ酢酸エステル、コンドロイチン硫酸ナトリウム、肝臓加水分解物、ニコチン酸アミド、カルニチン、パンテノール等が挙げられる。 In the liquid preparation composition for internal use of the present invention, a flavor containing other components than benzaldehyde, other medicinal components, ethanol, a pH adjuster, a preservative, and a colorant, as long as the adverse masking effect of kojin is not adversely affected , Solubilizer, glycerin, water and the like can be blended. Here, as other medicinal ingredients, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin E, vitamin E acetate, sodium chondroitin sulfate, liver hydrolyzate, nicotinamide, carnitine, panthenol and the like can be mentioned. .
また本発明の内用液剤組成物のｐＨは安定性の点から、４〜７が好ましく、特に４．５〜６．５が好ましい。 Moreover, 4-7 are preferable from the point of stability, and, as for pH of the liquid preparation for internal use of this invention, 4.5-6.5 are especially preferable.
本発明の内用液剤組成物はコウジンを有効量含有し、かつコウジン特有の異味がマスキングされ、服用感が良好であるから、コウジンの薬理作用、すなわち滋養強壮効果、食欲不振や胃もたれの改善効果、血行促進効果等が奏される。 The liquid preparation composition for internal use of the present invention contains an effective amount of kojin, masks the unique taste of kojin, and has a good feeling of administration, so that the pharmacological action of kojin, that is, nourishing tonicity, anorexia and stomach sag improvement The effect, blood circulation promotion effect, etc. are produced.
次に実施例を挙げて本発明を更に詳細に説明する。 EXAMPLES Next, an Example is given and this invention is demonstrated still in detail.
実施例１〜２５及び比較例１〜１４
表１〜表５に記載の処方に従い、内用液剤を製造し、その味を１０名のパネラーにより、５段階評価した。表１〜表５中の配合量は、内用液剤５０ｍＬ中の含有量（ｍｇ）である。
Examples 1-25 and Comparative Examples 1-14
According to the prescriptions shown in Tables 1 to 5, internal liquid preparations were produced, and the taste was evaluated on a 5-level scale by 10 panelists. The compounding amount in Tables 1 to 5 is the content (mg) in 50 mL of internal liquid preparation.
（１）内用液剤の製法
コウジン乾燥エキスの水溶液を加熱攪拌し、冷却後、ろ過したところへ、クエン酸、クエン酸ナトリウム、エリスリトール、スクラロース、アセスルファムカリウム、及び香料を加えｐＨ調整、ろ過、充てん、殺菌をして内用液剤とした。
(1) Manufacturing method for internal use Heating and stirring an aqueous solution of Koujin dry extract, cooling, filtering, adding citric acid, sodium citrate, erythritol, sucralose, acesulfame potassium, and fragrance, adjusting pH, filtering, filling Then, it was sterilized to obtain a liquid for internal use.
（２）味の評価方法
パネラー１０名に、コウジン特有の異味のマスキング効果及び全体の服用感（味）を５段階で評価させた。表１〜表５にはその平均値を示した。
５：極めて良好
４：良好
３：改善されていない
２：悪い
１：極めて悪い
(2) Taste Evaluation Method Ten panelists were allowed to evaluate the taste masking effect peculiar to Koujin and the overall feeling of use (taste) in five stages. Tables 1 to 5 show the average values.
5: Very good 4: Good 3: Not improved 2: Bad 1: Very bad
表１〜表５より、（Ａ）コウジン、（Ｂ）ベンズアルデヒド含有香料、（Ｃ）クエン酸又はその塩、並びにエリスリトール、スクラロース及びアセスルファムカリウムから選ばれる１種又は２種以上の甘味料を含有し、Ａ／Ｂ＝３０〜２００である本発明の内用液剤は、コウジン特有の異味が良好にマスキングされ、服用感（味）も良好であった。これに対し、Ａ／Ｂが３０〜２００の範囲外の場合（比較例１及び２）や、他の種々のフレーバーを用いた場合（比較例３〜８及び１０〜１４）や、他の高甘味度甘味料を用いた場合（比較例９）では、十分なマスキング効果が得られなかった。 From Table 1 to Table 5, it contains (A) Kojin, (B) benzaldehyde-containing fragrance, (C) citric acid or a salt thereof, and one or more sweeteners selected from erythritol, sucralose and acesulfame potassium. , A / B = 30 to 200, the liquid preparation for internal use of the present invention was well masked for the special taste of Koujin and also had a good feeling (taste). On the other hand, when A / B is outside the range of 30 to 200 (Comparative Examples 1 and 2), when other various flavors are used (Comparative Examples 3 to 8 and 10 to 14), In the case of using a sweetness degree sweetener (Comparative Example 9), a sufficient masking effect was not obtained.
実施例２６
コンドロイチン硫酸エステルナトリウム（９００ｍｇ）とエリスリトール（２０００ｍｇ）に水を加え加熱溶解後、トコフェロール酢酸エステル（１００ｍｇ）、パラオキシ安息香酸ブチル（７ｍｇ）、ポリオキシエチレン硬化ヒマシ油６０、濃グリセリン及び水で調製した可溶化液を加え、さらに、コウジン乾燥エキス（３００ｍｇ）（コウジンとして３０００ｍｇ）に水を加え、加熱処理し、ろ過したものを加える。溶解を確認後、ニコチン酸アミド（１２ｍｇ）、パンテノール（２０ｍｇ）、クエン酸（５０ｍｇ）、クエン酸ナトリウム（２５０ｍｇ）、安息香酸ナトリウム（３５ｍｇ）、スクラロース（９ｍｇ）、アセスルファムカリウム（６ｍｇ）、カラメル（５０ｍｇ）、ウメフレーバー（３３ｍｇ：小川香料株式会社製）、チリフレーバー（１７ｍｇ）を加えたのち、ｐＨ調整し５０ｍＬに調製したものを、ろ過、充てん、殺菌をして内用液剤とする。
Example 26
After adding water to sodium chondroitin sulfate ester (900 mg) and erythritol (2000 mg) and dissolving by heating, it was prepared with tocopherol acetate ester (100 mg), butyl paraoxybenzoate (7 mg), polyoxyethylene hydrogenated castor oil 60, concentrated glycerin and water. A solubilized solution is added, and water is added to Koujin dry extract (300 mg) (3000 mg as Koujin), followed by heat treatment and filtered. After confirming dissolution, nicotinamide (12 mg), panthenol (20 mg), citric acid (50 mg), sodium citrate (250 mg), sodium benzoate (35 mg), sucralose (9 mg), acesulfame potassium (6 mg), caramel (50 mg), Ume Flavor (33 mg: Ogawa Fragrance Co., Ltd.) and Chile Flavor (17 mg) were added, and the pH adjusted and adjusted to 50 mL was filtered, filled and sterilized to obtain an internal solution.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011222409A JP5891694B2 (en) | 2011-10-07 | 2011-10-07 | Internal liquid composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011222409A JP5891694B2 (en) | 2011-10-07 | 2011-10-07 | Internal liquid composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013082644A true JP2013082644A (en) | 2013-05-09 |
| JP5891694B2 JP5891694B2 (en) | 2016-03-23 |
Family
ID=48528232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011222409A Active JP5891694B2 (en) | 2011-10-07 | 2011-10-07 | Internal liquid composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5891694B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015112102A (en) * | 2013-12-16 | 2015-06-22 | ポッカサッポロフード＆ビバレッジ株式会社 | Umeboshi flavor composition, and method of imparting umeboshi flavor |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06277014A (en) * | 1993-03-31 | 1994-10-04 | Koichi Masago | Healthy beverage and its production |
| JP2001321114A (en) * | 2000-05-15 | 2001-11-20 | Nikken Kasei Kk | Sweetness composition and food and drink containing the same |
| JP2003171314A (en) * | 2001-09-26 | 2003-06-20 | Lion Corp | Oral administration solution composition |
-
2011
- 2011-10-07 JP JP2011222409A patent/JP5891694B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06277014A (en) * | 1993-03-31 | 1994-10-04 | Koichi Masago | Healthy beverage and its production |
| JP2001321114A (en) * | 2000-05-15 | 2001-11-20 | Nikken Kasei Kk | Sweetness composition and food and drink containing the same |
| JP2003171314A (en) * | 2001-09-26 | 2003-06-20 | Lion Corp | Oral administration solution composition |
Non-Patent Citations (1)
| Title |
|---|
| JPN6015042487; 周知・慣用技術集（香料）第ＩＩ部食品用香料 , 20000114, ｐｐ．１３９-１４０, 特許庁 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015112102A (en) * | 2013-12-16 | 2015-06-22 | ポッカサッポロフード＆ビバレッジ株式会社 | Umeboshi flavor composition, and method of imparting umeboshi flavor |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5891694B2 (en) | 2016-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2605495T3 (en) | Atomoxetine solution | |
| JP5839681B2 (en) | Liquid composition containing herbal extract | |
| JP4889948B2 (en) | An oral solution with excellent ingestion | |
| JP2012136492A (en) | Chinese oral liquid medicine improved in medicine-taking feeling | |
| JP2007238561A (en) | Paeoniflorin-containing jelly preparation | |
| JP5766021B2 (en) | Stable aqueous solution | |
| JP2002363105A (en) | Method for masking unpleasant taste and solution for oral administration | |
| JP2003231647A (en) | Oral liquid composition | |
| JP5891694B2 (en) | Internal liquid composition | |
| JP5083492B2 (en) | Liquid for internal use | |
| JP2011148776A (en) | Liquid preparation composition | |
| JP2012031080A (en) | Recovery agent for symptom of hangover | |
| JP2004161679A (en) | Liquid preparation for internal use | |
| JP2018131412A (en) | Chinese medicine semisolid pharmaceutical composition | |
| JP5992305B2 (en) | Composition for improving oral odor | |
| JP6686292B2 (en) | Amino acid-containing composition | |
| JP7287446B2 (en) | candy | |
| JP5992304B2 (en) | Oral body odor improving composition | |
| JP2013095670A (en) | Carbonic acid-containing internal liquid preparation | |
| JP2011231051A (en) | Oral jelly preparation containing vitamin b1 | |
| JP5266627B2 (en) | Oral composition | |
| JP6849281B2 (en) | Composition containing liver hydrolyzate and Houttuynia cordata extract | |
| JP2022023385A (en) | Peroral liquid composition | |
| JP2007217310A (en) | Oral refreshing composition | |
| JP4932253B2 (en) | Oral liquid composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140723 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150623 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150824 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151027 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151225 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160126 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160208 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5891694 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |